Shilpa Medicare’s 100% subsidiary -- Shilpa Pharma Lifesciences has received certificate of suitability (CEP) from EDQM (European Directorate for the Quality of Medicines & Healthcare) for API, Teriflunomide.
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis (MS). Teriflunomide has demonstrated clinical efficacy and safety in a number of large, multicenter, phase III clinical trials and is an attractive agent to add to the growing repertoire of available treatments for MS, as it has the benefit of oral administration.
This certificate is 25th CEP issued by EDQM to the company, which showcases its continued expertise and commitment to develop, manufacture and supply of quality-oriented products of global standards.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1581.95 |
Dr. Reddys Lab | 1126.55 |
Cipla | 1418.45 |
Lupin | 2009.65 |
Zydus Lifesciences | 887.55 |
View more.. |